Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2016 AND FEBRUARY 2018. Refer to TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens and TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | eribulin mesilate (Halaven®) | ||
| Formulation | 0.44 mg/ml solution for injection | ||
| Reference number | 1212 | ||
| Indication | Treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments |
||
| Company | Eisai Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 0916 | ||
| NMG meeting date | 16/03/2016 | ||
| AWMSG meeting date | 20/04/2016 | ||
| Ratification by Welsh Government | 29/04/2016 | ||
| Date of issue | 03/05/2016 | ||
| NICE guidance | TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (external link - opens in new window) TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (external link - opens in new window) |
||